Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$139.4 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Closing of $139.4 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ligand OmniAb\u00ae Partner Immunovant Announced Positive Topline Results from Phase 2a Trial of IMVT-1401 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Immunovant","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Receives $200 Million Strategic Investment from Roivant Sciences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Two New Development Programs for Batoclimab","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Pricing of $450 Million Common Stock Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Proposed Offering of $300 Million of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$492.1 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Immunovant

    Menu

    Immunovant

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Immunovant

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

              Details:

              IMVT-1402 is designed to be a potentially best-in-class neonatal anti-FcRn antibody, which is being evaluated for the treatment of IgG-mediated autoimmune diseases.

              Lead Product(s): IMVT-1402

              Therapeutic Area: Immunology Product Name: IMVT-1402

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Immunovant

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

              Details:

              The net proceeds will fund the acceleration of IMVT-1402 development. IMVT-1402 is designed to be a potentially best-in-class anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases.

              Lead Product(s): IMVT-1402

              Therapeutic Area: Immunology Product Name: IMVT-1402

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Leerink Partners

              Deal Size: $492.1 million Upfront Cash: Undisclosed

              Deal Type: Public Offering October 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Immunovant

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunovant Announces Pricing of $450 Million Common Stock Financing

              Details:

              The net proceeds will fund the acceleration of IMVT-1402 development. IMVT-1402 is designed to be a potentially best-in-class anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases.

              Lead Product(s): IMVT-1402

              Therapeutic Area: Immunology Product Name: IMVT-1402

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Leerink Partners

              Deal Size: $450.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering September 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Immunovant

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunovant Announces Proposed Offering of $300 Million of Common Stock

              Details:

              The net proceeds will fund the acceleration of IMVT-1402 development. IMVT-1402 is designed to be a potentially best-in-class anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases.

              Lead Product(s): IMVT-1402

              Therapeutic Area: Immunology Product Name: IMVT-1402

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Leerink Partners

              Deal Size: $300.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering September 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Immunovant

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

              Details:

              IMVT-1402 is designed to be a potentially best-in-class anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases. In the initial results of a Phase 1 clinical trial in healthy volunteers, IMVT-1402 demonstrated favorable pharmacodynamic and safety data.

              Lead Product(s): IMVT-1402

              Therapeutic Area: Immunology Product Name: IMVT-1402

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Immunovant

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

              Details:

              The company intends to use the net proceeds from this offering, together with its existing cash, to accelerate the development of IMVT-1402 (batoclimab), including the funding of a proposed pivotal trial.

              Lead Product(s): Batoclimab

              Therapeutic Area: Immunology Product Name: IMVT-1401

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: SVB Securities

              Deal Size: $75.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering October 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Immunovant

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

              Details:

              As with batoclimab, (IMVT-1402), potentially best-in-class IgG reduction formulated for same simple subcutaneous route of administration delivered in matter of seconds. IMVT1402 has been observed to have minimal or no impact on levels of albumin and LDL in animal studies.

              Lead Product(s): Batoclimab

              Therapeutic Area: Immunology Product Name: IMVT-1402

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Immunovant

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunovant Announces Two New Development Programs for Batoclimab

              Details:

              The Company’s investigational compound, HBM9161 (batoclimab), is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn)in Chronic Inflammatory Demyelinating Polyneuropathy and Graves’ Disease.

              Lead Product(s): Batoclimab

              Therapeutic Area: Neurology Product Name: HBM9161

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Immunovant

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

              Details:

              The trial will include an induction (primary efficacy) period during which Immunovant plans to study doses of 680mg and 340mg of batoclimab delivered weekly by subcutaneous injection.

              Lead Product(s): Batoclimab

              Therapeutic Area: Immunology Product Name: HBM9161

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Immunovant

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunovant Receives $200 Million Strategic Investment from Roivant Sciences

              Details:

              Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. Proceeds will fund continued development of IMVT-1401 in multiple indications.

              Lead Product(s): IMVT-1401

              Therapeutic Area: Immunology Product Name: RVT-1401

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Roivant Sciences

              Deal Size: $200.0 million Upfront Cash: Undisclosed

              Deal Type: Financing August 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY